BR112023001049A2 - Método para tratamento de doença de enxerto versus hospedeiro causada por transplante de célula-tronco hematopoiética - Google Patents
Método para tratamento de doença de enxerto versus hospedeiro causada por transplante de célula-tronco hematopoiéticaInfo
- Publication number
- BR112023001049A2 BR112023001049A2 BR112023001049A BR112023001049A BR112023001049A2 BR 112023001049 A2 BR112023001049 A2 BR 112023001049A2 BR 112023001049 A BR112023001049 A BR 112023001049A BR 112023001049 A BR112023001049 A BR 112023001049A BR 112023001049 A2 BR112023001049 A2 BR 112023001049A2
- Authority
- BR
- Brazil
- Prior art keywords
- stem cell
- hematopoietic stem
- host disease
- disease caused
- cell transplantation
- Prior art date
Links
- 208000009329 Graft vs Host Disease Diseases 0.000 title abstract 3
- 208000024908 graft versus host disease Diseases 0.000 title abstract 3
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010713637 | 2020-07-22 | ||
| PCT/CN2021/107575 WO2022017412A1 (zh) | 2020-07-22 | 2021-07-21 | 治疗造血干细胞移植后的移植物抗宿主病的方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023001049A2 true BR112023001049A2 (pt) | 2023-03-07 |
Family
ID=79728482
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023001049A BR112023001049A2 (pt) | 2020-07-22 | 2021-07-21 | Método para tratamento de doença de enxerto versus hospedeiro causada por transplante de célula-tronco hematopoiética |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230285393A1 (https=) |
| EP (1) | EP4186508A4 (https=) |
| JP (1) | JP7803924B2 (https=) |
| KR (1) | KR20230043891A (https=) |
| CN (2) | CN121846099A (https=) |
| AU (1) | AU2021313124A1 (https=) |
| BR (1) | BR112023001049A2 (https=) |
| CA (1) | CA3186564A1 (https=) |
| IL (1) | IL299985A (https=) |
| TW (2) | TW202216691A (https=) |
| WO (1) | WO2022017412A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL311447A (en) * | 2021-09-18 | 2024-05-01 | Beijing Tide Pharmaceutical Co Ltd | A solid form of a Rho-linked protein kinase inhibitor or a solvate thereof, a method of preparation and use thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120202793A1 (en) * | 2009-03-09 | 2012-08-09 | Paul Sweetnam | Rho kinase inhibitors |
| CN113620933A (zh) * | 2012-10-05 | 2021-11-09 | 卡德门企业有限公司 | Rho激酶抑制剂 |
| WO2018039539A1 (en) * | 2016-08-26 | 2018-03-01 | Lycera Corporation | Indazolyl-l,2,4-thiadiazolamines and related compounds for inhibition of rho-associated protein kinase and the treatment of disease |
| CN110582489B (zh) | 2017-06-30 | 2023-10-27 | 北京泰德制药股份有限公司 | Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途 |
| WO2019000682A1 (zh) * | 2017-06-30 | 2019-01-03 | 北京泰德制药股份有限公司 | Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途 |
| US10323023B2 (en) * | 2017-06-30 | 2019-06-18 | Beijing Tide Pharmaceutical Co., Ltd. | Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof |
| TWI818919B (zh) * | 2017-08-15 | 2023-10-21 | 美商歐米諾斯公司 | 用於治療和／ 或預防與造血幹細胞移植有關的移植物抗宿主病和／ 或瀰漫性肺泡出血和／ 或靜脈閉塞性病的方法 |
-
2021
- 2021-07-21 AU AU2021313124A patent/AU2021313124A1/en active Pending
- 2021-07-21 CN CN202610271426.3A patent/CN121846099A/zh active Pending
- 2021-07-21 CA CA3186564A patent/CA3186564A1/en active Pending
- 2021-07-21 TW TW110126814A patent/TW202216691A/zh unknown
- 2021-07-21 BR BR112023001049A patent/BR112023001049A2/pt unknown
- 2021-07-21 EP EP21845732.3A patent/EP4186508A4/en active Pending
- 2021-07-21 IL IL299985A patent/IL299985A/en unknown
- 2021-07-21 JP JP2023504356A patent/JP7803924B2/ja active Active
- 2021-07-21 WO PCT/CN2021/107575 patent/WO2022017412A1/zh not_active Ceased
- 2021-07-21 US US18/017,198 patent/US20230285393A1/en active Pending
- 2021-07-21 TW TW112113471A patent/TWI868660B/zh active
- 2021-07-21 CN CN202180059344.8A patent/CN116322670A/zh active Pending
- 2021-07-21 KR KR1020237005450A patent/KR20230043891A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023535035A (ja) | 2023-08-15 |
| EP4186508A1 (en) | 2023-05-31 |
| TW202216691A (zh) | 2022-05-01 |
| IL299985A (en) | 2023-03-01 |
| KR20230043891A (ko) | 2023-03-31 |
| CN116322670A (zh) | 2023-06-23 |
| WO2022017412A1 (zh) | 2022-01-27 |
| AU2021313124A1 (en) | 2023-03-09 |
| CN121846099A (zh) | 2026-04-14 |
| TWI868660B (zh) | 2025-01-01 |
| EP4186508A4 (en) | 2024-10-16 |
| US20230285393A1 (en) | 2023-09-14 |
| JP7803924B2 (ja) | 2026-01-21 |
| TW202327609A (zh) | 2023-07-16 |
| CA3186564A1 (en) | 2022-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023001195A2 (pt) | Composto ou racemato, estereoisômero, tautômero, composto isotopicamente rotulado, solvato, polimorfo, sal farmaceuticamente aceitável ou composto pró-fármaco do mesmo, composto, método de preparação para composto ou racemato, estereoisômero, tautômero, composto isotopicamente rotulado, solvato, polimorfo, sal farmaceuticamente aceitável ou composto de pró-fármaco, composição farmacêutica, método para tratar uma doença associada com a ativação do caminho alternativo de complemento, e, uso do composto | |
| CO2023001407A2 (es) | Compuestos de tetrahidropirazolo-pirazinil-dihidroimidazolona o tetrahidropirazolo-piridinil-dihidroimidazolona y métodos de uso de los mismos | |
| BR112021026214A2 (pt) | Método para tratamento de fibrose pulmonar idiopática | |
| MX2023007192A (es) | Inhibidores de prmt5. | |
| MX2024011056A (es) | Compuesto heterociclico para inducir la degradacion de la proteina kras mutante g12d. | |
| BR112021017354A2 (pt) | Método para o tratamento de doença hepática adiposa e/ou esteatoepatite | |
| ECSP22019360A (es) | Piperidinil-metil-purinaminas como inhibidores de nsd2 y antineoplásicos | |
| BR112021014525A8 (pt) | Inibidor de jak e método de preparação do mesmo | |
| BR112017017078A2 (pt) | composto, composição farmacêutica, uso de um composto, e, método para prevenir, gerenciar, tratar ou amenizar uma doença. | |
| CR20210477A (es) | Compuestos de aza-benzotiofeno y aza-benzofurano como antihelmínticos | |
| ZA202400988B (en) | Aak1 inhibitor and use thereof | |
| MX2023001671A (es) | Procedimiento y compuesto para su uso en el tratamiento y/o prevención de la netosis. | |
| BR112022020814A2 (pt) | Métodos para tratamento de síndrome de liberação de citocina | |
| MX2024010099A (es) | Derivado de pirazolopiridina y aplicacion del mismo en medicina. | |
| MX2025007797A (es) | Derivado de tetrahidrotiofeno y uso de este en medicina | |
| EA025948B1 (ru) | КОМБИНАЦИЯ ИНГИБИТОРА ФОСФАТИДИЛИНОЗИТ-3-КИНАЗЫ (PI3K) И ИНГИБИТОРА mTOR | |
| MX2021008010A (es) | Composiciones y métodos para tratar las enfermedades del hígado graso no alcohólico (nafld). | |
| DOP2023000060A (es) | Inhibidores de la línea-1 para tratar enfermedades antecedentes de la invención | |
| BR112022016448A2 (pt) | Método para tratamento de doença do enxerto contra hospedeiro crônica | |
| BR112023001049A2 (pt) | Método para tratamento de doença de enxerto versus hospedeiro causada por transplante de célula-tronco hematopoiética | |
| BR112023025251A2 (pt) | Composto ou sal, éster, solvato, pró-fármaco, derivado marcado com isótopo ou isômero farmaceuticamente aceitável deste, composição, composição farmacêutica e método para tratamento de uma doença ou distúrbio inibindo a transdução de sinal mediada por tyk2 | |
| BR112022002107A2 (pt) | Inibidor de vmat2 e método de preparação para o mesmo e aplicação do mesmo | |
| CL2020003143A1 (es) | Compuestos de ácido ascórbico y quinona en combinación con un agente antiparasitario para el tratamiento de una enfermedad parasitaria | |
| EP2150550A4 (en) | NEW CARBAMOYLOXY-ARYL-ALKAN-ARYLPIPERAZIN COMPOUND, PHARMACEUTICAL COMPOSITIONS WITH THE COMPOUND AND METHOD FOR THE TREATMENT OF PAIN, FEAR STATES AND DEPRESSION BY MEANS OF ADMINISTRATION OF THE COMPOUND | |
| MX2022011242A (es) | Inmunomodulación de o-het/aril azálidos. |